Research Article
Hypocalcemia with Immune Checkpoint Inhibitors: The Disparity among Various Reports
Table 1
Baseline characteristics of the study population.
| | | Pembrolizumab (n) | Nivolumab (n) | Ipilimumab (n) | Nivolumab-ipilimumab (n) |
| | Gender | | Male | 49 | 99 | 3 | 6 | | Female | 30 | 46 | 1 | 0 |
| | Cancer type | | Lung | 85 | 85 | | | | GI | 6 | 9 | | | | Melanoma | 4 | 25 | 4 | 5 | | Neuroendocrine | 1 | 4 | | | | RCC | 2 | 15 | | 1 | | Bladder | 5 | 2 | | | | Head and neck | 8 | | | | | Laryngeal | 2 | | | | | Prostate | 1 | | | | | Hodgkin lymphoma | 1 | | | | | HCC | | 1 | | | | Mesothelioma | | 2 | | |
| | Factors affecting calcium levels | | Metastasis to bone | 11 | 26 | | | | Calcium supplements | 6 | 10 | | 1 | | Vitamin D | 8 | 36 | 3 | 3 | | Bisphosphonates | 9 | 9 | 1 | | | History of neck radiation | 6 | | | | | History of parathyroidectomy | | | | | | >stage IIIB CKD | | 2 | | | | History of hypo/hyperparathyroidism | | | | |
| | Lost to follow-up | | Deceased | 15 | 25 | | | | Disease progression | 21 | 69 | | | | Treatment completed | 4 | 10 | 1 | | | Treatment changed | 1 | | | | | Hospice | 5 | 9 | | | | Changed MD | 1 | 2 | | | | No-show | 1 | | | | | Drug intolerance | 3 | 4 | | | | Ongoing | 28 | 10 | | | | Insurance | | 2 | | | | Lost to follow-up | | 4 | | | | Change in comorbidities | | 2 | | |
|
|
